Barcelona-based Almirall SA is deepening its reliance on generative artificial intelligence (GenAI) for drug discovery and development. The company, which specializes in dermatological indications, entered a three-year collaboration with Microsoft to employ the big tech’s GenAI and advanced analytics capabilities to analyze datasets and strengthen its own technology platform.
Almirall’s CEO, Carlos Gallardo, was quoted in a press release as saying the partnership will “transform our ways of working...